National Hemophilia Foundation - for all bleeding disorders https://www.hemophilia.org/ en <!-- THEME DEBUG --> <!-- THEME HOOK: 'views_view_field' --> <!-- BEGIN OUTPUT from 'core/themes/stable/templates/views/views-view-field.html.twig' --> NHF Responds to New CMS Guidance <!-- END OUTPUT from 'core/themes/stable/templates/views/views-view-field.html.twig' --> https://www.hemophilia.org/__%3C%21--%20THEME%20DEBUG%20--%3E_%3C%21--%20THEME%20HOOK%3A%20%27views_view_field%27%20--%3E_%3C%21--%20BEGIN%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20--%3E_/news/nhf-responds-to-new-cms-guidance_%3C%21--%20END%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20--%3E__ <!-- THEME DEBUG --> <!-- THEME HOOK: 'views_view_field' --> <!-- BEGIN OUTPUT from 'core/themes/stable/templates/views/views-view-field.html.twig' --> <p><em><strong>Media Contact: </strong></em><br /> Brett Spitale, VP of Advancement<br /> <a href="mailto:bspitale@hemophilia.org">bspitale@hemophilia.org</a><br /> 646-784-0368</p> <!-- END OUTPUT from 'core/themes/stable/templates/views/views-view-field.html.twig' --> Jul 23, 2021 iostrin https://www.hemophilia.org/__%3C%21--%20THEME%20DEBUG%20--%3E_%3C%21--%20THEME%20HOOK%3A%20%27views_view_field%27%20--%3E_%3C%21--%20BEGIN%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20--%3E_5581_%3C%21--%20END%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20--%3E__ <!-- THEME DEBUG --> <!-- THEME HOOK: 'views_view_field' --> <!-- BEGIN OUTPUT from 'core/themes/stable/templates/views/views-view-field.html.twig' --> UCSD Offers Virtual CME-Accredited Trainings on Musculoskeletal Ultrasound <!-- END OUTPUT from 'core/themes/stable/templates/views/views-view-field.html.twig' --> https://www.hemophilia.org/__%3C%21--%20THEME%20DEBUG%20--%3E_%3C%21--%20THEME%20HOOK%3A%20%27views_view_field%27%20--%3E_%3C%21--%20BEGIN%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20--%3E_/news/ucsd-offers-virtual-cme-accredited-trainings-on-musculoskeletal-ultrasound_%3C%21--%20END%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20--%3E__ <!-- THEME DEBUG --> <!-- THEME HOOK: 'views_view_field' --> <!-- BEGIN OUTPUT from 'core/themes/stable/templates/views/views-view-field.html.twig' --> <p>The University of California at San Diego (UCSD) School of Medicine has launched a new CME-accredited curriculum designed to offer more accessible, comprehensive virtual training on point-of-care musculoskeletal ultrasound (MSKUS).</p> <p>The trainings focus on utilizing MSKUS for the evaluation of primary joints, including the ankles, knees, and elbows. Health care providers will also develop their skills in MSKUS for application to other arthritic conditions and other musculoskeletal syndromes, including hemophilic arthropathy.</p> <!-- END OUTPUT from 'core/themes/stable/templates/views/views-view-field.html.twig' --> Jul 13, 2021 jangarola https://www.hemophilia.org/__%3C%21--%20THEME%20DEBUG%20--%3E_%3C%21--%20THEME%20HOOK%3A%20%27views_view_field%27%20--%3E_%3C%21--%20BEGIN%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20--%3E_5578_%3C%21--%20END%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20--%3E__ <!-- THEME DEBUG --> <!-- THEME HOOK: 'views_view_field' --> <!-- BEGIN OUTPUT from 'core/themes/stable/templates/views/views-view-field.html.twig' --> FDA Places Clinical Hold on Sigilon’s Investigational Hemophilia Therapy <!-- END OUTPUT from 'core/themes/stable/templates/views/views-view-field.html.twig' --> https://www.hemophilia.org/__%3C%21--%20THEME%20DEBUG%20--%3E_%3C%21--%20THEME%20HOOK%3A%20%27views_view_field%27%20--%3E_%3C%21--%20BEGIN%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20--%3E_/news/fda-places-clinical-hold-on-sigilons-investigational-hemophilia-therapy_%3C%21--%20END%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20--%3E__ <!-- THEME DEBUG --> <!-- THEME HOOK: 'views_view_field' --> <!-- BEGIN OUTPUT from 'core/themes/stable/templates/views/views-view-field.html.twig' --> <p>The U.S. Food and Drug Administration (FDA) has placed a clinical hold on Sigilon Therapeutics’ phase 1/2 study of SIG-001 in patients with severe or moderately severe hemophilia A.</p> <!-- END OUTPUT from 'core/themes/stable/templates/views/views-view-field.html.twig' --> Jul 12, 2021 jangarola https://www.hemophilia.org/__%3C%21--%20THEME%20DEBUG%20--%3E_%3C%21--%20THEME%20HOOK%3A%20%27views_view_field%27%20--%3E_%3C%21--%20BEGIN%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20--%3E_5576_%3C%21--%20END%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20--%3E__ <!-- THEME DEBUG --> <!-- THEME HOOK: 'views_view_field' --> <!-- BEGIN OUTPUT from 'core/themes/stable/templates/views/views-view-field.html.twig' --> Kevin Child Scholarship Deadline Set for August 2nd! <!-- END OUTPUT from 'core/themes/stable/templates/views/views-view-field.html.twig' --> https://www.hemophilia.org/__%3C%21--%20THEME%20DEBUG%20--%3E_%3C%21--%20THEME%20HOOK%3A%20%27views_view_field%27%20--%3E_%3C%21--%20BEGIN%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20--%3E_/news/kevin-child-scholarship-deadline-set-for-august-2nd_%3C%21--%20END%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20--%3E__ <!-- THEME DEBUG --> <!-- THEME HOOK: 'views_view_field' --> <!-- BEGIN OUTPUT from 'core/themes/stable/templates/views/views-view-field.html.twig' --> <p>NHF is very pleased to announce that the Kevin Child Scholarship (KCS) application deadline has been set for August 2, 2021! The scholarship is named in tribute to Kevin Child, who died of AIDS in 1989, shortly before graduating from college. It is awarded annually to a student with hemophilia who is about to enter or currently enrolled in a program of higher education.  </p> <!-- END OUTPUT from 'core/themes/stable/templates/views/views-view-field.html.twig' --> Jul 8, 2021 jangarola https://www.hemophilia.org/__%3C%21--%20THEME%20DEBUG%20--%3E_%3C%21--%20THEME%20HOOK%3A%20%27views_view_field%27%20--%3E_%3C%21--%20BEGIN%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20--%3E_5575_%3C%21--%20END%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20--%3E__ <!-- THEME DEBUG --> <!-- THEME HOOK: 'views_view_field' --> <!-- BEGIN OUTPUT from 'core/themes/stable/templates/views/views-view-field.html.twig' --> Learn More About Shared Decision Making in Hemophilia <!-- END OUTPUT from 'core/themes/stable/templates/views/views-view-field.html.twig' --> https://www.hemophilia.org/__%3C%21--%20THEME%20DEBUG%20--%3E_%3C%21--%20THEME%20HOOK%3A%20%27views_view_field%27%20--%3E_%3C%21--%20BEGIN%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20--%3E_/news/learn-more-about-shared-decision-making-in-hemophilia_%3C%21--%20END%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20--%3E__ <!-- THEME DEBUG --> <!-- THEME HOOK: 'views_view_field' --> <!-- BEGIN OUTPUT from 'core/themes/stable/templates/views/views-view-field.html.twig' --> <p><span><span><span><span><span><span>Shared decision making (SDM), the concept by which patients and healthcare providers work closely together to arrive at personalized treatment-related decisions, can have significant positive impacts for individuals with hemophilia.</span></span></span></span></span></span></p> <!-- END OUTPUT from 'core/themes/stable/templates/views/views-view-field.html.twig' --> Jun 24, 2021 jangarola https://www.hemophilia.org/__%3C%21--%20THEME%20DEBUG%20--%3E_%3C%21--%20THEME%20HOOK%3A%20%27views_view_field%27%20--%3E_%3C%21--%20BEGIN%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20--%3E_5567_%3C%21--%20END%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20--%3E__ <!-- THEME DEBUG --> <!-- THEME HOOK: 'views_view_field' --> <!-- BEGIN OUTPUT from 'core/themes/stable/templates/views/views-view-field.html.twig' --> New Paper Explores Shared Decision Making in Hemophilia <!-- END OUTPUT from 'core/themes/stable/templates/views/views-view-field.html.twig' --> https://www.hemophilia.org/__%3C%21--%20THEME%20DEBUG%20--%3E_%3C%21--%20THEME%20HOOK%3A%20%27views_view_field%27%20--%3E_%3C%21--%20BEGIN%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20--%3E_/news/new-paper-explores-shared-decision-making-in-hemophilia_%3C%21--%20END%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20--%3E__ <!-- THEME DEBUG --> <!-- THEME HOOK: 'views_view_field' --> <!-- BEGIN OUTPUT from 'core/themes/stable/templates/views/views-view-field.html.twig' --> <p><span><span><span><span><span><span>A new paper published in <i>The Journal of Haemophilia Practice</i> advances the concept of shared decision making (SDM) between the hemophilia patient and their healthcare provider (HCP).</span></span></span></span></span></span></p> <!-- END OUTPUT from 'core/themes/stable/templates/views/views-view-field.html.twig' --> Jun 22, 2021 jangarola https://www.hemophilia.org/__%3C%21--%20THEME%20DEBUG%20--%3E_%3C%21--%20THEME%20HOOK%3A%20%27views_view_field%27%20--%3E_%3C%21--%20BEGIN%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20--%3E_5556_%3C%21--%20END%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20--%3E__ <!-- THEME DEBUG --> <!-- THEME HOOK: 'views_view_field' --> <!-- BEGIN OUTPUT from 'core/themes/stable/templates/views/views-view-field.html.twig' --> New Article Offers Scientific Overview of AAV Vectors and Hemophilia Gene Therapy <!-- END OUTPUT from 'core/themes/stable/templates/views/views-view-field.html.twig' --> https://www.hemophilia.org/__%3C%21--%20THEME%20DEBUG%20--%3E_%3C%21--%20THEME%20HOOK%3A%20%27views_view_field%27%20--%3E_%3C%21--%20BEGIN%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20--%3E_/news/new-article-offers-scientific-overview-of-aav-vectors-and-hemophilia-gene-therapy_%3C%21--%20END%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20--%3E__ <!-- THEME DEBUG --> <!-- THEME HOOK: 'views_view_field' --> <!-- BEGIN OUTPUT from 'core/themes/stable/templates/views/views-view-field.html.twig' --> <p>A new article, “Emerging Immunogenicity and Genotoxicity Considerations of Adeno-Associated Virus Vector Gene Therapy for Hemophilia,” was published in the <em>Journal of Clinical Medicine </em>(JCM).<br /> </p> <!-- END OUTPUT from 'core/themes/stable/templates/views/views-view-field.html.twig' --> Jun 18, 2021 jangarola https://www.hemophilia.org/__%3C%21--%20THEME%20DEBUG%20--%3E_%3C%21--%20THEME%20HOOK%3A%20%27views_view_field%27%20--%3E_%3C%21--%20BEGIN%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20--%3E_5554_%3C%21--%20END%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20--%3E__ <!-- THEME DEBUG --> <!-- THEME HOOK: 'views_view_field' --> <!-- BEGIN OUTPUT from 'core/themes/stable/templates/views/views-view-field.html.twig' --> New Affordable Care Act Ruling Benefits Chronic Disease Patients <!-- END OUTPUT from 'core/themes/stable/templates/views/views-view-field.html.twig' --> https://www.hemophilia.org/__%3C%21--%20THEME%20DEBUG%20--%3E_%3C%21--%20THEME%20HOOK%3A%20%27views_view_field%27%20--%3E_%3C%21--%20BEGIN%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20--%3E_/news/new-affordable-care-act-ruling-benefits-chronic-disease-patients_%3C%21--%20END%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20--%3E__ <!-- THEME DEBUG --> <!-- THEME HOOK: 'views_view_field' --> <!-- BEGIN OUTPUT from 'core/themes/stable/templates/views/views-view-field.html.twig' --> <h4>FOR IMMEDIATE RELEASE</h4> <p><strong>Media Contact</strong><br /> Ilana Ostrin<br /> <a href="mailto:iostrin@hemophilia.org">iostrin@hemophilia.org</a><br /> 212-328-3769</p> <!-- END OUTPUT from 'core/themes/stable/templates/views/views-view-field.html.twig' --> Jun 17, 2021 vprice https://www.hemophilia.org/__%3C%21--%20THEME%20DEBUG%20--%3E_%3C%21--%20THEME%20HOOK%3A%20%27views_view_field%27%20--%3E_%3C%21--%20BEGIN%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20--%3E_5553_%3C%21--%20END%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20--%3E__ <!-- THEME DEBUG --> <!-- THEME HOOK: 'views_view_field' --> <!-- BEGIN OUTPUT from 'core/themes/stable/templates/views/views-view-field.html.twig' --> NHF Marks the 40th Anniversary of the HIV Epidemic <!-- END OUTPUT from 'core/themes/stable/templates/views/views-view-field.html.twig' --> https://www.hemophilia.org/__%3C%21--%20THEME%20DEBUG%20--%3E_%3C%21--%20THEME%20HOOK%3A%20%27views_view_field%27%20--%3E_%3C%21--%20BEGIN%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20--%3E_/news/nhf-marks-the-40th-anniversary-of-the-hiv-epidemic_%3C%21--%20END%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20--%3E__ <!-- THEME DEBUG --> <!-- THEME HOOK: 'views_view_field' --> <!-- BEGIN OUTPUT from 'core/themes/stable/templates/views/views-view-field.html.twig' --> <p><em><strong>FOR PUBLIC COMMENT - JUNE 3, 2021</strong></em><br /> </p> <!-- END OUTPUT from 'core/themes/stable/templates/views/views-view-field.html.twig' --> Jun 3, 2021 iostrin https://www.hemophilia.org/__%3C%21--%20THEME%20DEBUG%20--%3E_%3C%21--%20THEME%20HOOK%3A%20%27views_view_field%27%20--%3E_%3C%21--%20BEGIN%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20--%3E_5537_%3C%21--%20END%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20--%3E__ <!-- THEME DEBUG --> <!-- THEME HOOK: 'views_view_field' --> <!-- BEGIN OUTPUT from 'core/themes/stable/templates/views/views-view-field.html.twig' --> BioMarin Presents Positive Safety and Efficacy Data for their Hemophilia A Gene Therapy <!-- END OUTPUT from 'core/themes/stable/templates/views/views-view-field.html.twig' --> https://www.hemophilia.org/__%3C%21--%20THEME%20DEBUG%20--%3E_%3C%21--%20THEME%20HOOK%3A%20%27views_view_field%27%20--%3E_%3C%21--%20BEGIN%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20--%3E_/news/biomarin-presents-positive-safety-and-efficacy-data-for-their-hemophilia-a-gene-therapy_%3C%21--%20END%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20--%3E__ <!-- THEME DEBUG --> <!-- THEME HOOK: 'views_view_field' --> <!-- BEGIN OUTPUT from 'core/themes/stable/templates/views/views-view-field.html.twig' --> <p>BioMarin recently reported key findings from preclinical studies of their investigational, gene therapy Roctavian (valoctocogene roxaparvovec), which was developed for the treatment of adults with severe hemophilia A. The findings were presented at the American Society of Gene &amp; Cell Therapy (ASGCT) Virtual Meeting, which was held May 11-14, 2021.</p> <!-- END OUTPUT from 'core/themes/stable/templates/views/views-view-field.html.twig' --> May 27, 2021 jangarola https://www.hemophilia.org/__%3C%21--%20THEME%20DEBUG%20--%3E_%3C%21--%20THEME%20HOOK%3A%20%27views_view_field%27%20--%3E_%3C%21--%20BEGIN%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20--%3E_5528_%3C%21--%20END%20OUTPUT%20from%20%27core/themes/stable/templates/views/views-view-field.html.twig%27%20--%3E__